An industry group representing companies that manufactured the copycat versions of Eli Lilly's (NYSE:LLY) highly popular weight loss therapy tirzepatide sued the U.S. FDA on Monday over the agency's decision to declare an end to the drug's shortage last week.

Machine-learning drug development company Insitro has inked three agreements with Eli Lilly for new medicines for metabolic diseases.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli Lilly 's (NYSE: LLY) popular Mounjaro and Zepbound. However, the U.S. Food and Drug Administration (FDA) recently removed both drugs from its shortage list, indicating that supply can now keep up with current demand.

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, claiming its action to remove Eli Lilly’s Mounjaro and Zepbound from its drug shortage list is a “reckless and arbitrary decision—lacking any semblance of lawful process.

Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.

While additional drugs in the same class are sure to earn FDA approval in the coming years, Eli Lilly is well positioned in the segment. Given its immense resources, it should be able to maintain a significant market share.

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs from its shortage list last week,

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.

A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug Administration over the agency’s decision to remove Lilly’s medications from its shortage list.

A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's tirzepatide from an official shortages list.